A prognostic signature consisting of N6-methyladenosine modified mRNAs demonstrates clinical potential in prediction of biochemical recurrence and guidance on precision therapy in prostate cancer

Novel biomarkers are urgently needed to improve the prediction of clinical outcomes and guide personalized treatment for prostate cancer (PCa) patients. However, the role of N6-methyladenosine (m6A) modifications in PCa initiation and progression remains largely elusive. In our study, we collected b...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Jianming, Chen, Jiahong, Lin, Zhuoyuan, Liu, Qinwei, Zhong, Chuanfan, Cai, Zhouda, Jia, Zhenyu, Zhong, Weide, Liang, Yingke, Cai, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130690/
https://www.ncbi.nlm.nih.gov/pubmed/37060728
http://dx.doi.org/10.1016/j.tranon.2023.101670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130690/
https://www.ncbi.nlm.nih.gov/pubmed/37060728
http://dx.doi.org/10.1016/j.tranon.2023.101670

Ejemplares similares